Angiotensin I (Human, Mouse, Rat) Mechanisms, Clinical Value

Angiotensin I (Human, Mouse, Rat): Mechanisms, Clinical Value, and Research Applications in Cardiovascular and Renal Disease
Introduction [Related: exendin 4]
Angiotensin I (Ang I) is a decapeptide precursor within the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis in mammals. Ang I is generated by the enzymatic cleavage of angiotensinogen by renin, predominantly in the liver, and is subsequently converted to the potent vasoconstrictor angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) primarily in the lungs and vascular endothelium (Fyhrquist & Saijonmaa, 2008, J Intern Med). The availability of synthetic Ang I peptides for human, mouse, and rat models, such as those provided by APExBIO Technology LLC, enables precise experimental manipulation of the RAS in preclinical and translational research. The mechanism of action of Ang I is indirect; it serves as a substrate for ACE, which cleaves two amino acids from the C-terminus to generate Ang II. Ang II then binds to angiotensin II type 1 (AT1) and type 2 (AT2) receptors, mediating vasoconstriction, aldosterone secretion, sodium retention, and pro-inflammatory signaling (Paul et al., 2006, Physiol Rev). The study of Ang I, therefore, is foundational for understanding the regulation and dysregulation of cardiovascular and renal physiology, as well as for the development of therapeutic interventions targeting the RAS. [Related: 740y-p]
Clinical Value and Applications [Related: Tris(2-carboxyethyl)phosphine Hydrochloride]
The clinical value of Ang I lies primarily in its central role within the RAS and its utility as a research tool for dissecting the pathophysiology of hypertension, heart failure, chronic kidney disease, and related disorders. Synthetic Ang I peptides are indispensable in: 1. **Pharmacodynamic Studies:** Ang I is used to evaluate the efficacy of ACE inhibitors and angiotensin receptor blockers (ARBs) by quantifying the conversion of Ang I to Ang II and subsequent physiological responses (Krum et al., 1998, Circulation). 2. **Disease Modeling:** Administration of Ang I in animal models (mouse, rat) allows for the induction of hypertension, cardiac remodeling, and renal injury, facilitating the study of disease mechanisms and therapeutic interventions (Crowley et al., 2006, Hypertension). 3. **Biomarker Development:** Measurement of Ang I levels in plasma or tissues serves as a biomarker for RAS activity and therapeutic response in clinical and preclinical studies (Campbell, 2017, Clin Sci). 4. **Drug Discovery:** Ang I is a substrate in high-throughput screening assays for novel ACE inhibitors, ARBs, and renin inhibitors, supporting the development of next-generation antihypertensive agents (Oparil et al., 2018, Nat Rev Nephrol). The availability of Ang I peptides for human, mouse, and rat species ensures translational relevance and cross-species comparability in RAS research.
Key Challenges and Pain Points Addressed
Current challenges in cardiovascular and renal research include the need for reliable, species-specific reagents to model human disease, the complexity of RAS regulation, and the limitations of existing therapeutic strategies. Synthetic Ang I peptides address several pain points: - **Species Specificity:** Sequence variations between human, mouse, and rat Ang I can affect enzymatic processing and receptor interactions. Access to species-matched peptides ensures accurate modeling and interpretation of experimental data (Paul et al., 2006). - **Reproducibility:** High-purity, well-characterized Ang I peptides reduce variability in experimental outcomes, supporting reproducibility and rigor in preclinical research. - **Mechanistic Insights:** Direct administration of Ang I allows for the dissection of upstream versus downstream RAS effects, distinguishing between renin-dependent and ACE-dependent mechanisms. - **Therapeutic Evaluation:** Ang I enables the assessment of drug efficacy and off-target effects in the context of intact or manipulated RAS pathways, informing clinical translation. These advantages are particularly relevant in the context of emerging therapies targeting alternative RAS components (e.g., neprilysin inhibitors, direct renin inhibitors) and in the study of RAS dysregulation in non-cardiovascular diseases, such as metabolic syndrome and COVID-19 (Vaduganathan et al., 2020, NEJM).
Literature Review
A robust body of literature supports the centrality of Ang I in cardiovascular and renal research: 1. **Fyhrquist & Saijonmaa (2008, J Intern Med):** This review delineates the molecular biology of the RAS, emphasizing the enzymatic conversion of Ang I to Ang II and the clinical implications of RAS modulation in hypertension and heart failure. 2. **Paul et al. (2006, Physiol Rev):** The authors provide a comprehensive overview of the RAS, including species differences in angiotensinogen and Ang I sequences, and their impact on experimental outcomes. 3. **Crowley et al. (2006, Hypertension):** Using mouse models, the study demonstrates that chronic Ang I infusion induces hypertension and end-organ damage, validating its use in disease modeling. 4. **Krum et al. (1998, Circulation):** This clinical trial assesses the pharmacodynamics of ACE inhibitors by measuring Ang I and Ang II levels, highlighting the utility of Ang I as a biomarker and research tool. 5. **Campbell (2017, Clin Sci):** The review discusses the measurement of angiotensin peptides in plasma and tissues, underscoring the importance of Ang I quantification in clinical and translational research. 6. **Oparil et al. (2018, Nat Rev Nephrol):** The article reviews advances in RAS-targeting therapies, including the use of Ang I in preclinical drug screening. 7. **Vaduganathan et al. (2020, NEJM):** The authors explore the role of RAS modulation in COVID-19, noting the relevance of Ang I and related peptides in understanding disease mechanisms and therapeutic responses. Collectively, these studies establish Ang I as a cornerstone of RAS research, with broad applications in basic science, translational medicine, and drug development.
Experimental Data and Results
Experimental studies utilizing synthetic Ang I peptides have elucidated key aspects of RAS biology and therapeutic intervention: - **Hypertension Models:** Chronic infusion of Ang I in rodents induces sustained increases in blood pressure, cardiac hypertrophy, and renal fibrosis, recapitulating features of human hypertension and heart failure (Crowley et al., 2006). These models are instrumental for testing ACE inhibitors, ARBs, and novel RAS modulators. - **Pharmacodynamic Assessment:** In clinical and preclinical studies, administration of Ang I allows for the quantification of ACE activity by measuring the conversion rate to Ang II. For example, Krum et al. (1998) demonstrated that ACE inhibition leads to elevated Ang I and reduced Ang II levels, correlating with blood pressure reduction. - **Biomarker Validation:** Measurement of Ang I levels in plasma and tissues serves as a surrogate for RAS activity. Campbell (2017) highlighted the use of mass spectrometry and immunoassays for precise quantification, facilitating patient stratification and therapeutic monitoring. - **Species Differences:** Paul et al. (2006) reported that sequence variations in Ang I among human, mouse, and rat affect enzymatic processing and receptor binding, underscoring the importance of species-matched peptides in translational research. These findings support the utility of Ang I as both a mechanistic probe and a translational tool in cardiovascular and renal research.
Usage Guidelines and Best Practices
The effective use of Ang I (human, mouse, rat) peptides in research requires adherence to best practices in experimental design, handling, and data interpretation: 1. **Peptide Handling:** Synthetic Ang I peptides should be stored at -20°C or below, protected from moisture and repeated freeze-thaw cycles. Reconstitution in sterile, buffered solutions (e.g., PBS, saline) is recommended for in vivo and in vitro applications. 2. **Dosing and Administration:** For animal studies, dosing regimens should be based on published protocols and adjusted for species, strain, and experimental objectives. Chronic infusion via osmotic minipumps or acute bolus injection are common approaches (Crowley et al., 2006). 3. **Species Matching:** Use of species-specific Ang I sequences is critical for accurate modeling and interpretation, as sequence differences can affect enzymatic and receptor interactions (Paul et al., 2006). 4. **Analytical Methods:** Quantification of Ang I and downstream peptides should employ validated assays (e.g., ELISA, LC-MS/MS) with appropriate controls and standards (Campbell, 2017). 5. **Ethical Considerations:** All animal experiments should comply with institutional and national guidelines for the care and use of laboratory animals. Meticulous experimental planning and execution are essential for generating reproducible, interpretable data with Ang I peptides.
Future Research Directions
Ongoing and future research with Ang I (human, mouse, rat) is poised to address several emerging questions in cardiovascular, renal, and systemic disease: - **Alternative RAS Pathways:** Investigation of non-canonical RAS components (e.g., angiotensin-(1-7), ACE2) and their interplay with Ang I in health and disease (Oparil et Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406